Research tool page — not in the public editorial index
This company can still be explored inside Wall Street Score, but this URL remains noindex and is not eligible for Google-served ads until source-specific publisher curation is documented and the public research-quality checks pass.
Edap Tms S.a.
EDAP · Price history
Company & revenue
About Edap Tms S.a.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
How they make money
EDAP TMS S.A. generates revenue through the development, manufacturing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices. The company utilizes a business model that combines the sale of capital equipment with recurring revenue streams derived from the sale of associated consumables and the provision of maintenance services for its installed base of medical devices.
Products & services
The company provides robotic energy-based medical devices, primarily focusing on Focal One HIFU technology for prostate cancer treatment, as well as distribution and ESWL (Extracorporeal Shock Wave Lithotripsy) equipment.
Brands & revenue mix
Primary commercial brand for robotic HIFU technology.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract manufacturing and component suppliers — The company relies on various third-party suppliers for components and contract manufacturing services to produce its medical devices; specific supplier names are not disclosed.Source
Strengths
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 56.9% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Total debt increased 365.2% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
23
Poor
Financial Strength
24
Business Quality / Moat
30
Management
33
Growth Quality
1
Risk / Durability
13
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
25
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
37/100
Building Historical Record
Model Score 37/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for EDAP
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving EDAP's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can EDAP fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is EDAP's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for EDAP to reach sustainable profitability?
- •What future growth or profitability would be needed to justify EDAP's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Opportunity Score
25
Market Cap
$178.2M
P/E Ratio
-4.7
EPS
$-1.01
52-Week High
$5.05
52-Week Low
$1.21
Beta
-0.08
Analyst Target
$10.00
Shares Outstanding
37.4M
Total Revenue
$62.9M
Total Debt
$41.7M
Dividend
No current dividend
Liquidation Value / Share
$-0.09
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Notices for EDAP
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-31.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on EDAP.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Focal One robotic HIFU technology.
- +Established installed base generating recurring revenue.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Specialties industry.
- −Dependence on third-party suppliers and contract manufacturers.
- −Regulatory risks associated with medical device approvals and clinical trials.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
17
Sep 21, 2026
Change
Unchanged
Current Score
17
Oct 1, 2026
Category Changes
EDAP score was unchanged.
Projected Score
Projected Score
12
Projected Change
-5.0 points
Preliminary comparable-period financial changes suggest decline of approximately 5.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$4.75
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.9M | $70.7M | $64.1M | $60.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $33.3M | $40.7M | $37.6M | $36.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $29.6M | $30.1M | $26.6M | $24.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $9.3M | $8.6M | $7.7M | $7.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $48.1M | $45.0M | $39.4M | $37.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $71.7M | $55.3M | $47.1M | $44.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$25.4M | -$25.0M | -$15.9M | -$18.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$27.2M | -$25.2M | -$20.5M | -$19.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $11.1M | $791K | $236K | $232K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$38.5M | -$29.3M | -$18.7M | -$20.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $339K | $71K | $289K | $644K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$38.9M | -$29.3M | -$19.0M | -$21.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.01 | $-0.78 | $-0.51 | $-0.57 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 37.48M | 37.44M | 37.29M | 37.00M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 37.48M | 37.44M | 37.29M | 37.00M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$6.9M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.39
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+365.2%
Cash Change
-27.8%
Margin Change
-174.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 56.9%. EPS increased 160.0%. Cash declined 27.8%. Total debt increased 365.2%. Net income margin declined by 174.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - SpecialtiesRumor Mill · EDAP
Corporate developments & opportunities
No reviewed developments match this filter.
The reliability percentage measures the strength of the supporting evidence—not the probability that the event will occur or that the stock will rise. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial